Pharmaceutical Technology on MSN7d
AstraZeneca and Alteogen agree on ALT-B4 platform tech"AstraZeneca and Alteogen agree on ALT-B4 platform tech" was originally created and published by Pharmaceutical Technology, a ...
AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...
AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...
Monday was a busy day for AstraZeneca, which also paid up to $1 billion to acquire Belgian biotech EsoBiotec and its cell therapy pipeline and technology.
Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, ...
The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology ...
Cambridge: AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase ...
AstraZeneca (AZN) and Alteogen have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform ...
The Chosun Ilbo on MSN6d
S. Korea's biotech sector kicks off 2025 with multi-billion-dollar dealsS. Koreas biotech sector kicks off 2025 with multi-billion-dollar deals K-Bio firms secure nearly $2.3 billion in licensing ...
AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...
AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback